Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;54(8):763-772.
doi: 10.1111/hepr.14047. Epub 2024 Apr 18.

Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021

Hirayuki Enomoto  1 , Norio Akuta  2 , Hayato Hikita  3 , Goki Suda  4 , Jun Inoue  5 , Nobuharu Tamaki  6 , Kiyoaki Ito  7 , Takemi Akahane  8 , Tomokazu Kawaoka  9 , Asahiro Morishita  10 , Eiichi Ogawa  11 , Ryosuke Tateishi  12 , Hitoshi Yoshiji  8
Affiliations

Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021

Hirayuki Enomoto et al. Hepatol Res. 2024 Aug.

Abstract

Aim: A nationwide survey in 2018 showed decreasing involvement of viral hepatitis and increasing involvement of nonviral liver diseases in the etiology of liver cirrhosis (LC) in Japan. An updated nationwide survey was undertaken in 2023.

Methods: Cases of LC diagnosed between 2018 and 2021 were collected from 75 institutions, and the etiologies of LC were investigated. In addition, the data obtained were compared with the results of previous studies.

Results: Among the 15 517 cases, alcohol-related liver disease (ALD)-associated LC was the most frequent cause (n = 5,487, 35.4%). Hepatitis C virus-associated LC, nonalcoholic steatohepatitis (NASH)-associated LC, and hepatitis B virus-associated LC were ranked as second, third, and fourth, respectively. In comparison to the previous survey, the ratios of viral hepatitis-associated LC decreased (HBV: from 11.5% to 8.1%; HCV: from 48.2% to 23.4%), while the ratios of ALD-associated LC and NASH-associated LC increased (from 19.9% to 35.4% and from 6.3% to 14.6%, respectively). Regarding cases of LC with hepatocellular carcinoma (n = 5906), HCV-associated LC (1986 cases, 33.6%) was the most frequent cause. Alcohol-related liver disease-associated LC, NASH-associated LC, and HBV-associated LC were the second-, third-, and fourth-ranked causes, respectively. In comparison to the previous survey, as the cause of hepatocellular carcinoma-complicated LC, HCV-associated LC decreased from 60.3% to 33.6%, while the ratios of ALD-associated LC and NASH-associated LC increased from 14.2% to 28.6% and from 4.2% to 14.0%, respectively.

Conclusions: The major causes of LC in Japan are suggested to have been shifting from viral hepatitis to nonviral chronic liver diseases.

Keywords: liver cirrhosis; nationwide survey; steatotic liver disease; viral hepatitis.

PubMed Disclaimer

References

REFERENCES

    1. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. https://doi.org/10.1002/hep.29800
    1. Bhattacharya D, Aronsohn A, Price J, Lo Re V. AASLD‐IDSA HCV Guidance Panel. Hepatitis C guidance 2023 update: AASLD‐IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023. (in press; Epub ahead of print).
    1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: chair; EASL Governing Board representative: panel members EASL recommendations on the treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–1218.
    1. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016‐2021. Towards ending viral hepatitis. https://www.who.int/publications/i/item/WHO‐HIV‐2016.06
    1. Setoyama H, Tanaka Y, Kanto T. Seamless support from screening to anti‐HCV treatment and HCC/ decompensated cirrhosis: subsidy programs for HCV elimination. Glob Health Med. 2021;3(5):335–342. https://doi.org/10.35772/ghm.2021.01079

LinkOut - more resources